This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated April 9, 2021 to its short form base prospectus dated March 31, 2021.
Halifax, Nova Scotia--(Newsfile Corp. - November 18, 2021) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce the launch of a new research program to explore the leading attributes of its unique, proprietary gold nanorod technology together with leading experts in the field of bioengineering.
The Company has entered a collaboration with Dr. Warren Chan, distinguished professor, and Canada Research Chair in Nanobioengineering & Director of the Institute of Biomedical Engineering at the University of Toronto. Under the terms of the memorandum of understanding executed with the University of Toronto, Dr. Chan will provide Sona with consultation on the design and execution of appropriate studies to determine the biocompatibility of its gold nanorod technology.
Sona's research collaborations will leverage the expertise and scientific leadership of a group of third-party, respected scientists and entrepreneurs to work with Sona's team, bringing together nanoparticle production technology with advanced physical chemistry techniques and biological studies.
This program will seek to substantiate the biocompatibility of Sona's proprietary, gold nanorod manufacturing processes and provide a foundation for further research programs, with a view to identifying the most promising potential medical applications for Sona's technology.
Dr. Warren Chan, Director of the Institute of Bioengineering at the University of Toronto, commented, "The biocompatibility of nanomaterials will be an important component to the unlocking of new, potentially life-saving, medical nanotechnology applications and so our study will explore Sona Nanotech's gold nanorods as a safe, non-toxic material for use 'in-vivo'."
Sona Nanotech president and Chief Scientific Officer, Darren Rowles commented, "We are delighted to be working with Dr. Chan, one of the most important nanotechnology scientists in the world, and we are excited to explore with him the unique attributes and benefits our technology may bring to enabling new, important biomedical applications."
https://www.newsfilecorp.com/release/104178